University of Chile

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Retrieved on: 
Tuesday, November 21, 2023

AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail.

Key Points: 
  • AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail.
  • Management will be joined by three esteemed thought leaders in the field of endocrinology:
    Andrew Dauber, MD, Chief of Endocrinology at Children's National Medical Center, Washington, D.C.
    Fernando Cassorla, MD, Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research, University of Chile
    Virtual KOL Event: Review of Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency Wednesday, December 6, 2023 | 1:30 PM EST
    To register for the virtual KOL Event, please click through the link here .

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

Retrieved on: 
Tuesday, November 7, 2023

AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) today announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all primary and secondary endpoints. Data from the OraGrowtH210 Trial demonstrated annualized height velocity (AHV) on the 1.6 mg/kg dose of orally administered LUM-201 of 8.2 cm/yr at six months and 8.0 cm/yr at 12 months on treatment,* in line with historical data in moderate pediatric growth hormone deficiency (PGHD) patients and within the targeted 2 cm/yr margin of the comparator injectable recombinant growth hormone (rhGH) arm. Data also provided preliminary validation of the predictive enrichment marker (PEM) strategy, with prespecified primary and secondary outcomes met, de-risking our patient selection for our Phase 3 program. Data from the OraGrowtH212 Trial confirmed that LUM-201’s unique pulsatile mechanism produces an increase in growth rates while restoring growth hormone secretion and IGF-1 to within normal ranges †, with levels substantially below those produced by exogenous injectable rhGH.†† Additionally, data from a small subset of 10 subjects combined 1.6 and 3.2 mg/kg dosage of LUM-201 in both OraGrowtH210 and OraGrowtH212 trials demonstrated the sustained effectiveness of AHV up to 24 months. Furthermore, the safety profile for LUM-201 remained clean throughout both Phase 2 studies, with no safety concerns identified in either of our Phase 2 trials conducted thus far.

Key Points: 
  • Data also provided preliminary validation of the predictive enrichment marker (PEM) strategy, with prespecified primary and secondary outcomes met, de-risking our patient selection for our Phase 3 program.
  • The OraGrowtH210 trial met its primary objective, with 6-month AHV data of 8.2 cm/yr supporting the 1.6 mg/kg as the optimal dose for a Phase 3 clinical trial.
  • Eighteen and 24-month growth data were available for 10 subjects from the OraGrowtH210 and OraGrowtH212 Trials who met AHV criteria per protocol at 12 months.
  • Every participant in the OraGrowtH212 Trial met the criteria for Patient PEM positivity, ensuring their potential responsiveness to LUM-201.

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Retrieved on: 
Tuesday, November 7, 2023

AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that topline results met primary and secondary endpoints for its Phase 2 Dose-Finding OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos Pharma’s predictive enrichment marker (PEM) strategy. Lumos also announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Lumos also announced its financial results for the quarter ended September 30, 2023.
  • The Company expects cash use of approximately $9.0 to $10.0 million in the fourth quarter of 2023.
  • Net Loss – The net loss for the quarter ended September 30, 2023 was $8.3 million compared to a net loss of $7.3 million for the same period in 2022.
  • Lumos Pharma ended the third quarter 2023 with 7,914,582 shares outstanding.

Lundin Mining Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023

Copper production was lower than the prior year quarter primarily due to lower grades partially offset by higher throughput.

Key Points: 
  • Copper production was lower than the prior year quarter primarily due to lower grades partially offset by higher throughput.
  • Current quarter production costs and copper cash cost of $2.19/lb were higher than the prior year quarter largely owing to higher contractor and maintenance costs and unfavorable foreign exchange.
  • Nickel cash cost in the quarter of $2.07/lb was higher than the prior year quarter primarily due to lower by-product credits and higher production costs.
  • Production costs during the quarter were lower than the prior year quarter despite higher sales, primarily due to reduced electricity costs.

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

Retrieved on: 
Wednesday, June 21, 2023

AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.

Key Points: 
  • Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting, held in Chicago, Illinois, June 15-18, 2023.
  • Cassorla and Tansey will be available to answer questions following their formal presentations.
  • To register for the virtual KOL Event, please click through the link HERE .
  • Cassorla and Tansey gave two oral presentations in the Update on Growth Disorders session at the 2023 ENDO Meeting.

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

Retrieved on: 
Thursday, May 25, 2023

Lumos Pharma will host a virtual Key Opinion Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where Drs.

Key Points: 
  • Lumos Pharma will host a virtual Key Opinion Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where Drs.
  • Fernando Cassorla and Michael Tansey will review interim data evaluating oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the ENDO Meeting.
  • is currently Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research of the University of Chile, a position he has held since 1993.
  • Dr. Tansey also currently serves as Clinical Director for Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Iowa.

Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

Retrieved on: 
Monday, May 8, 2023

AUSTIN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 Trial were reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society (PES), held in San Diego, California, May 5-8, 2023. Data from the interim analysis of its OraGrowtH212 Trial were also presented in a poster session during the conference.

Key Points: 
  • Data from the interim analysis of its OraGrowtH212 Trial were also presented in a poster session during the conference.
  • Lead Author – Andrew Dauber, MD, Chief of Endocrinology, Children’s National Medical Center, Washington, D.C.
  • No treatment-related Serious Adverse Events (SAEs) and no meaningful safety signals observed in either laboratory values, adverse event data, or in electrocardiogram values.
  • Pending the final analysis in 4Qtr 2023, the optimal dose currently appears to be 1.6 mg/kg/day.

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

Retrieved on: 
Wednesday, May 3, 2023

AUSTIN, Texas, May 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the quarter ended March 31, 2023.

Key Points: 
  • (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the quarter ended March 31, 2023.
  • “With both our Phase 2 OraGrowtH210 and OraGrowtH212 Trials evaluating oral LUM-201 in moderate (idiopathic) PGHD fully enrolled, we look forward to announcing top line results in the fourth quarter of 2023,” said Rick Hawkins, Chair and CEO of Lumos Pharma.
  • The Company expects an average cash use of approximately $9.5 to $10.5 million per quarter through 2023.
  • Lumos Pharma had 8,183,296 shares outstanding as of March 31, 2023.

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

Retrieved on: 
Thursday, April 27, 2023

AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 Trial will be reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society (PES), held in San Diego, California, May 5-8, 2023. Data from the interim analysis of its OraGrowtH212 Trial are also being presented as a poster during the medical meeting.

Key Points: 
  • AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 Trial will be reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society (PES) , held in San Diego, California, May 5-8, 2023.
  • Data from the interim analysis of its OraGrowtH212 Trial are also being presented as a poster during the medical meeting.
  • Lead Author – Andrew Dauber, MD, Chief of Endocrinology, Children’s National Medical Center, Washington, D.C.
  • Title (Abstract 6197) – Observed IGF-1 Serum Concentration Increase Within Normal Range After Prolonged Daily Oral LUM-201 Administration in Idiopathic Pediatric Growth Hormone Deficiency from the OraGrowtH212 Trial: Interim Analysis Data
    Lead Author – Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile
    Saturday, May 6, 12:30 PM – 2:00 PM local time: Poster presentation by David B. Karpf, MD, Chief Medical Officer, Lumos Pharma, and Adjunct Clinical Professor, Endocrinology, Stanford University School of Medicine

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

Retrieved on: 
Sunday, March 5, 2023

AUSTIN, Texas, March 05, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that additional data from its OraGrowtH212 trial was included in an oral presentation of interim results at the 2023 International Meeting of Pediatric Endocrinology (IMPE), held in Buenos Aires, Argentina, March 4-7, 2023. Data from the interim analysis of its OraGrowtH210 trial are also being presented as a poster during the conference.

Key Points: 
  • Data from the interim analysis of its OraGrowtH210 trial are also being presented as a poster during the conference.
  • “The additional data presented at IMPE on our OraGrowtH212 Trial reinforce the conclusions drawn about the PK/PD profile of LUM-201 from the interim data analysis we conducted last November,” said Rick Hawkins, Chairman and CEO of Lumos Pharma.
  • “The data update continued to show a dose-dependent increase of growth hormone pulsatility, correlation of pulsatility with increased height velocity, and a durable response out to 12 months.
  • The poster presentation highlighted the results of the interim analysis of data for 41 subjects from the OraGrowtH210 Trial.